Liudmila Zhaunova on a global Flo app study linking higher physical activity to lower perimenopause symptom burden.
|Articles|August 1, 2000
Postmenopausal HRT and CHD: clinical implications of recent randomized trial res
Results of the HERS, ERA, and WHI trials suggest a conservative approach to use of HRT in women with evidence of CHD. Dose and duration of therapy may be key to the risk-benefit equation.
Advertisement
Advertisement
Related to this article
The 16-item Perimenopause Symptom Scale showed strong reliability and validity among 1255 women aged 35 to 59 years in the United States.
Risa Kagan, MD, on bone health prevention in primary care and why baseline bone density testing should come before age 65.
Patients with 3 or more adverse pregnancy outcomes had lower odds of postpartum contraceptive use in a PRAMS analysis of 222,412 individuals.
Risk factors cast a wide net in preeclampsia prediction, but biomarkers could add precision, according to Dallas Reed, MD.
Risa Kagan, MD, on why the menopause transition is a critical window for bone loss and how women can preserve bone mass.
This FAQ summarizes a Special Report discussion on testosterone pellet therapy in women and advice for hesitant prescribers.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
Advertisement
Advertisement